Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model

Transplantation

Volumn 82, Issue 2, 2006, Pages 175-179

  Shimmura, Hiroaki ^a   Tanabe, Kazunari ^a,c   Habiro, Katsuyoshi ^b   Abe, Ryo ^b   Toma, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NONE   (Japan)

Author keywords

Heart transplantation; Mice; Mizoribine; Mycophenolate mofetil

Indexed keywords

MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CELL PROLIFERATION; DRUG ANTAGONISM; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOPHENOLIC ACID; RIBONUCLEOSIDES; TIME FACTORS;

EID: 33746442395     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226227.79142.31     Document Type: Article

References (39)

1. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10(1 Pt 2): 77-84.
2. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22(4): 1659-1662.
3. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443-a new, potent immunosuppressive agent. Transplantation 1991; 51(1): 27-31.
4. Bechstein WO, Schilling M, Steele DM, et al. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993; 25(1 Pt 1): 702-703.
5. D'Alessandro AM, Rankin M, McVey J, et al. Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone. Transplantation 1993; 55(4): 695-700.
6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
7. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391-396.
8. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65(11): 1450-1454.
9. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66(4): 507-515.
10. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7(5): 442-450.
11. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68(2): 261-266.
12. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 199; 6(7): 575-597.
13. Uchida H, Yokota K, Akiyama N, et al. Effectiveness of a new drug, bredinin, on canine kidney allotransplant survival. Transplant Proc 1979; 11(1): 865-870.
14. Suzuki S, Hijioka T, Sakakibara I, Amemiya H. The synergistic effect of cyclosporine and mizoribine on heterotopic heart and partial-lung transplantation in rats. Transplantation 1987; 43(5): 743-744.
15. Tanabe K, Tokumoto T, Shimmura H, et al. Synergistic effect of high-dose mizoribine and low-dose tacrolimus on renal allograft survival in nonhuman primates. Transplant Proc 2002; 34(5): 1428.
16. Inou T, Kusaba R, Takahashi I, et al. Clinical trial of Bredinin in renal transplantation. Transplant Proc 1980; 12(3): 526-528.
17. Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int 2002; 44(2): 205-209.
18. Aihara Y, Miyamae T, Ito S, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int 2002; 44(2): 199-204.
19. Tanabe K, Tokumoto T, Ishikawa N, et al. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression. Transplant Proc 1999; 31(7): 2877-2879.
20. Abe R, Ryan JJ, Finkelman FD, Hodes RJ. T cell recognition of Mls. T cell clones demonstrate polymorphism between Mlsa, Mlsc, and Mlsd. J Immunol 1987; 138(2): 373-379.
21. Tomita Y, Zhang QW, Yoshikawa M, et al. Improved technique of heterotopic cervical heart transplantation in mice. Transplantation 1997; 64(11): 1598-1601.
22. Vogl M, Weigel G, Seebacher G, et al. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring. Ther Drug Monit 1999; 21(6): 638-643.
23. Hosotsubo H, Takahara S, Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr 1988; 432: 340-345.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27.
25. Chou TC. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet 1994; 19: 91.
26. Gan L, Seyedsayamdost MR, Shuto S, et al. The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase. Biochemistry 2003; 42(4): 857-863.
27. Kohler GA, Gong X, Bentink S, et al. The functional basis of mycophenolic acid resistance in Candida albicans IMP dehydrogenase. J Biol Chem 2005; 280(12): 11295-11302.
28. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33(2): 175-183.
29. Okubo M, Chen XM, Kamata K, et al. Suppressive effect of mizoribine on humoral antibody production in DBA/2 mice. Transplantation 1986; 41(4): 495-498.
30. Hirohata S, Nakanishi K, Yanagida T. Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine. Clin Exp Immunol 2000; 120(3): 448-453.
31. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165(5): 2374-2381.
32. Allison AC, Kowalski WJ, Muller CJ, et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25(3 Suppl 2): 67-70.
33. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33(2): 161-173.
34. Quemeneur L, Flacher M, Gerland LM, et al. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002; 169(5): 2747-2755.
35. Turka LA, Dayton J, Sinclair G, et al. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 1991; 87(3): 940-948.
36. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992; 41(4): 671-676.
37. Sugiyama K, Satoh H, Saito K, et al. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl Int 2005; 18(5): 590-595.
38. Liu D, Kobayashi T, Nagasaka T, et al. Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transpl Int 2005; 18(4): 401-407.
39. Ohtomo Y, Fujinaga S, Takada M, et al. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol 2005; 20(12): 1744-1749.